Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04989387 · ClinicalTrials.gov registry record · Phase 1
Study of INCA 0186 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT04989387 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 57 participants.
The verdict
NCT04989387, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
This is an open-label, nonrandomized, multicenter, dose escalation, and dose expansion first-in human (FIH) Phase 1 study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCA00186 when given alone or in combination with INCB106385 and/or retifanlimab in participants with specific advanced solid tumors; squamous cell carcinoma of the head and neck (SCCHN) and specified gastrointestinal (GI) malignancies have been selected as indications of interest for this study. Participants with CD8 T-cell-positive tumors will be selected as these tumors are more likely to respond to immunotherapy.
Interventions
- DRUG Retifanlimab
- DRUG INCB106385
- DRUG INCA00186
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2024-09-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04989387
The ClinicalTrials.gov registry entry for NCT04989387 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Retifanlimab is the first listed.
NCT04989387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04989387 about?
NCT04989387 is a clinical study titled "Study of INCA 0186 in Subjects With Advanced Solid Tumors". This is an open-label, nonrandomized, multicenter, dose escalation, and dose expansion first-in human (FIH) Phase 1 study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCA00186 when given alone or in combination with INCB106385 and/or retifanlimab in parti...
What is the current status of trial NCT04989387?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2021-10-04. Estimated completion is 2024-09-19.
What interventions are being tested in trial NCT04989387?
The interventions under investigation include: Retifanlimab (DRUG), INCB106385 (DRUG), INCA00186 (DRUG).
Who is sponsoring clinical trial NCT04989387?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.